Myriad Genetics expands Precise MRD cancer test to three tumor types
Go back to Myriad Genetics expands Precise MRD cancer test to three tumor types| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 5.61 -0.09 (1.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.70 | 52 Week High | $45.34 | |||
| Open | $5.71 | 52 Week Low | $15.92 | |||
| Day High | $5.77 | P/E | 2.41 | |||
| Day Low | $5.58 | EPS | $2.33 | |||
| Volume | 867,631 | |||||
